Aldeyra Therapeutics, Inc. — Fiscal 2014 Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2014. Aldeyra is an early-stage biotechnology company developing NS2 and other aldehyde-trapping compounds for immune-mediated, inflammatory, orphan, and related diseases. NS2 was the lead product candidate, with planned Phase II trials in Sjögren-Larsson Syndrome and noninfectious anterior uveitis. The company had no approved products or product revenue and had six full-time employees at year-end.
Financial performance and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $3.7 million | $1.5 million |
| General and administrative expense | $3.6 million | $2.1 million |
| Loss from operations | $7.3 million | $3.7 million |
| Net income (loss) | $(5.2) million | $13.1 million |
| Net loss (income) attributable to common stockholders | $(9.6) million | $1.1 million income |
| Net cash used in operating activities | $4.8 million | $1.7 million |
| Cash and cash equivalents at year-end | $8.5 million | $3.3 million |
| Credit facility outstanding | $1.4 million | $1.4 million |
| Accumulated deficit | $46.5 million | $41.3 million |
| Total stockholders’ equity | $6.3 million | $(40.2) million |
Operating results do not provide a meaningful revenue or operating-margin profile because the company is pre-commercial. The 2014 net loss included a $4.1 million deemed dividend related to the conversion of preferred stock and approximately $2.3 million of income from changes in the fair value of preferred-stock warrant liabilities. Stock-based compensation was $2.0 million.
Cash provided by financing activities was $10.1 million, primarily from the May 2014 initial public offering of 1.5 million shares at $8.00 per share, which generated approximately $10.1 million of net proceeds. Management stated that year-end cash, January 2015 private-placement proceeds of approximately $9.1 million, and available credit were expected to fund operations through approximately the end of 2016, but not commercialization or substantial additional development requested by regulators.
Material changes versus the prior comparable period
- Research and development expense increased by $2.2 million, reflecting greater preclinical, manufacturing, clinical, and personnel spending.
- General and administrative expense increased by $1.5 million, driven primarily by higher insurance, legal, and personnel costs and the expenses of operating as a public company.
- Net cash used in operations increased from $1.7 million to $4.8 million.
- The 2013 net income was largely affected by non-cash changes in the fair value of preferred-stock rights and warrant liabilities; these instruments were converted, exercised, or otherwise eliminated in connection with the 2014 IPO.
- Redeemable preferred stock was converted into common stock in the IPO, resulting in year-end stockholders’ equity of $6.3 million versus a $40.2 million deficit at December 31, 2013.
- The company amended its Square 1 Bank facility to provide for up to $5.0 million of term loans, including a potential $3.0 million Tranche B loan contingent on positive Phase II data in SLS or noninfectious anterior uveitis.
Guidance, outlook, commentary, risks, and unusual items
- Management expected to initiate Phase II trials in 2015: an approximately 12-patient, eight-week topical SLS study and an approximately 45-patient, six-week noninfectious anterior uveitis study. Trial timing and designs remained subject to regulatory and other input.
- Management expected clinical-trial data in the second half of 2015 and planned to nominate a new oral aldehyde-trap candidate in 2015.
- NS2 had completed a Phase I eye-drop study in 48 healthy volunteers and appeared well tolerated, but had not demonstrated efficacy in humans and had not been administered to humans through routes other than the eye-drop formulation.
- All product candidates remained subject to successful clinical development, regulatory approval, manufacturing qualification, reimbursement, and market acceptance. The company had no product approved for sale.
- The business was substantially dependent on NS2, an unproven product candidate and therapeutic approach. The company expected continuing operating losses and required substantial additional capital.
- Debt was secured by company assets, including intellectual property, and contained operating and financial covenants. Default could permit acceleration of repayment and seizure of pledged assets.
- The company relied extensively on contract research organizations, consultants, and third-party manufacturers and had no commercial manufacturing agreements.
- The CyDex/Ligand license and supply agreement could require up to $2.15 million of milestone payments and low-single-digit royalties on applicable net sales if commercialization occurred.
- Contractual obligations included approximately $1.4 million of credit-facility principal, approximately $188,000 of operating-lease obligations, and potential executive severance obligations of up to approximately $1.3 million. License milestones were excluded because their timing was uncertain.
- The company reported no material pending litigation. Management stated that a previously identified material weakness in internal control over financial reporting had been remediated as of December 31, 2014, but future deficiencies remained a risk.
Most important facts for investors to verify
- Whether the planned 2015 Phase II trials were initiated, completed, and produced statistically and clinically meaningful efficacy results.
- The company’s subsequent cash usage, financing activity, runway, and ability to access the contingent Tranche B debt.
- Whether NS2 or any other candidate obtained orphan-drug designation, regulatory approval, or additional IND authorization.
- The terms, dilution, and warrant overhang associated with the January 2015 private placements and any later financings.
- Compliance with Square 1 Bank covenants and the consequences of any default or acceleration.
- The status and enforceability of the company’s NS2 patent portfolio and its Ligand license obligations.
- Whether clinical manufacturing, regulatory, reimbursement, or competitive developments materially changed the commercial opportunity.